The Dose Planning of BNCT for Brain Tumors
Radiation dose in BNCT and tumor cell survival relationship was studied to estimate the cure dose of tumors. SCCVII tumors, squamous cell carcinoma model of mouse, were used. The radiation doses were calculated from the10B-concentration measured by prompt γ—ray spectrometry and thermal neutron fluence. The radiation dose in Gy (D) vs. cell surviving fraction (SF) relationships were -InSF=−0.235+1.219*D (γ=0.984), -InSF=0.0833+0.961*D (y=0.990), and -1nSF=−0.013+1.141*D (γ=0.991) for BPA, BSH and NCT alone, respectively. Tumor control probability (TCP) vs. D relationship was calculated according to the following equation: TCP=exp(−n) and n=N*SF, where N was the initial number of clonogen. In calculation, N in 1 g tumor was postulated to be 105 according to the reported data on several type human tumors. TCP90 (90% tumor control probability) doses were around 11 Gy and 14 Gy for BPA and BSH, respectively. This dose planning has been applied to BNCT for brain tumors since June 1993. Two representative cases were reported. The first was the patient of 57 years old female with glioblastoma in the left temporal lobe treated using BSH. The radiation dose delivered in the deepest tumor site by high LET particles (α and p) was 16.5 Gy. Three weeks later, complete clearance of the tumor was demonstrated by MRI. The second was the case of 16 years old boy with malignant astrocytoma treated by BPA. PET study revealed the accumulation of BPA in the tumor with tumor/blood ratio of 3.5, and blood 10B-concentration was 6.7 ppm following administration of BPA-fluctose complex (BPA, 8g=120 mg/kg). Tumor 10B- concentration was estimated to be 23.5ppm. The radiation dose delivered in the deepest tumor point by high LET particles was 9.7 Gy. Seven months after BNCT, MRI demonstrated complete regression of the tumor.
KeywordsBoron Neutron Capture Therapy Neutron Fluence Survive Fraction Dose Planning Left Temporal Lobe
Unable to display preview. Download preview PDF.
- 1.Nelson, D.F., McDonald, J.F., Lapham, L.N., Qazi, R., Rubin, P., Central nervous system In: Clinical Oncology, A multidisciplinary approach for physicians and students. 7th. edit. (ed. Philip Rubin), Saunders Company, Philadelphia, 617–644, 1993.Google Scholar
- 2.Hatanaka, H. Boron-neutron capture therapy for tumors. In: Glioma (Eds.) Karim/Law, Springer-Verlag. Berlin Heidelberg, 233–249, 1991.Google Scholar
- 4.Kobayashi, T., Kanda, K., Ujeno, Y., Fukuda, H., Ando, K., Hiratsuka, J., Mishima, Y., Ichihashi, M. Irradiation conditions based on absorbed dose estimation in boron neutron capture therapy for superficially located malignant melanoma. Radiat. Biol. Res. Commu. 25, 53–64, 1990.Google Scholar
- 5.ICRP. Recommendations of the International Commission on Radiological Protection. Report 26, Annals of ICRP, Vol. I. No. 3. Pergamon, Oxford, 1977.Google Scholar
- 6.Withers, H.R., Peters, L.J. Biological aspects of radiation therapy. In: Textbook of radio-therapy. ed. G.H. Fletcher, Philadelphia, Lea and Febiger, 103–179, 1980.Google Scholar
- 8.Mulcahy,R.T., Sieman,D.W., Sutherland, R.M. Basic principles of radiobiology. In: Clinical Oncology, A multidisciplinary approach for physicians and students. 7th. edit. (ed. Philip Rubin), Saunders Company, Philadelphia, 51–70, 1993.Google Scholar
- 9.Coderre,J.A., Glass,J.D., Fairchild,R.G., Roy, U., Cohen, S., Fand, I. Selective targeting of boronophenylalanine to melanoma for neutron capture therapy. Cancer Res. 47, 6377–6383, 1987.Google Scholar